A Phase 1 interventional study of Empagliflozin/Metformin XR, FDC and Empagliflozin/Metformin XR FDC in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-08.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combination (FDC) tablets containing empagliflozin \& metformin and the single tablets of empagliflozin and metformin when administered singularly.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Any deviation from healthy condition
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 fixed dose combination (FDC) tablet vs. 3 single tablets under fasted conditions
Drug: 25 mg Empagliflozin/1000 mg Metformin XR, FDC · Drug: 1 tablet Empagliflozin/2 tablets Metformin XR
1 fixed dose combination (FDC) tablet vs. 3 single tablets under fed conditions
Drug: Empagliflozin/Metformin XR, FDC · Drug: 1 tablet Empagliflozin/2 tablets Metformin XR
2 fixed low dose combination (FDC) tablets vs. 4 single tablets under fed conditions
Drug: Empagliflozin/Metformin XR FDC · Drug: 1 tablet Empagliflozin/3 tablets Metformin XR
Drug pages: Empagliflozin · Metformin
Experimental: high dose empagliflozin/metformin XR, FDC tablet
Drug pages: Empagliflozin · Metformin
Experimental: low dose empagliflozin/metformin XR, FDC tablet
Drug pages: Empagliflozin · Metformin
Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
Active Comparator: 1x empagliflozin/2x metformin XR tablets
Active Comparator: 1x empagliflozin/3x metformin XR tablets
Active Comparator: 1x empagliflozin/2x metformin XR tablets
Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC 0-tz); Empagliflozin
Area under the concentration -time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz); Empagliflozin
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
AUC 0-tz (Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point); Metformin
AUC 0-tz (area under the concentration -time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point); Metformin
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Cmax (Maximum Measured Concentration of the Analyte in Plasma); Empagliflozin
Cmax (maximum measured concentration of the analyte in plasma); Empagliflozin
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Cmax (Maximum Measured Concentration of the Analyte in Plasma); Metformin
Cmax (maximum measured concentration of the analyte in plasma); Metformin
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
AUC 0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity); Empagliflozin
AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Empagliflozin
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
AUC 0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity); Metformin
AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Metformin
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
| Milestone | High Dose, Fasted: 1 FDC Tablet First, Then 3 Single Tablets | High Dose, Fasted: 3 Single Tablets First, Then 1 FDC Tablet | High Dose, Fed: 1 FDC Tablet First, Then 3 Single Tablets | High Dose, Fed: 3 Single Tablets First, Then 1 FDC Tablet | Low Dose, Fasted: 2 FDC Tablets First, Then 4 Single Tablets | Low Dose, Fasted: 4 Single Tablets First, Then 2 FDC Tablets |
|---|---|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 | 12 | 12 |
| Completed | 12 | 11 | 12 | 12 | 12 | 12 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Not treated | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | High Dose, Fasted: 1 FDC Tablet First, Then 3 Single Tablets | High Dose, Fasted: 3 Single Tablets First, Then 1 FDC Tablet | High Dose, Fed: 1 FDC Tablet First, Then 3 Single Tablets | High Dose, Fed: 3 Single Tablets First, Then 1 FDC Tablet | Low Dose, Fasted: 2 FDC Tablets First, Then 4 Single Tablets | Low Dose, Fasted: 4 Single Tablets First, Then 2 FDC Tablets |
|---|---|---|---|---|---|---|
| Started | 12 | 11 | 12 | 12 | 12 | 12 |
| Completed | 12 | 11 | 12 | 12 | 12 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Area under the concentration -time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz); Empagliflozin
| nmol*h/L | High Dose, Fasted: 1 FDC Tablet | High Dose, Fasted: 3 Single Tablets | High Dose, Fed: 1 FDC Tablet | High Dose, Fed: 3 Single Tablets | Low Dose, Fasted: 2 FDC Tablets | Low Dose, Fasted: 4 Single Tablets |
|---|---|---|---|---|---|---|
| Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC 0-tz); Empagliflozin | 6430 ± 22.3 | 6430 ± 21.7 | 5690 ± 21.0 | 5850 ± 19.6 | 7160 ± 19.5 | 7110 ± 20.5 |
AUC 0-tz (area under the concentration -time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point); Metformin
| ng*h/mL | High Dose, Fasted: 1 FDC Tablet | High Dose, Fasted: 3 Single Tablets | High Dose, Fed: 1 FDC Tablet | High Dose, Fed: 3 Single Tablets | Low Dose, Fasted: 2 FDC Tablets | Low Dose, Fasted: 4 Single Tablets |
|---|---|---|---|---|---|---|
| AUC 0-tz (Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point); Metformin | 6350 ± 32.8 | 6700 ± 28.9 | 13000 ± 23.6 | 13100 ± 21.1 | 10200 ± 38.5 | 10300 ± 38.3 |
AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Empagliflozin
| nmol*h/L | High Dose, Fasted: 1 FDC Tablet | High Dose, Fasted: 3 Single Tablets | High Dose, Fed: 1 FDC Tablet | High Dose, Fed: 3 Single Tablets | Low Dose, Fasted: 2 FDC Tablets | Low Dose, Fasted: 4 Single Tablets |
|---|---|---|---|---|---|---|
| AUC 0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity); Empagliflozin | 6510 ± 22.9 | 6490 ± 21.6 | 5800 ± 21.8 | 5970 ± 20.5 | 7240 ± 19.7 | 7180 ± 20.8 |
Cmax (maximum measured concentration of the analyte in plasma); Empagliflozin
| nmol/L | High Dose, Fasted: 1 FDC Tablet | High Dose, Fasted: 3 Single Tablets | High Dose, Fed: 1 FDC Tablet | High Dose, Fed: 3 Single Tablets | Low Dose, Fasted: 2 FDC Tablets | Low Dose, Fasted: 4 Single Tablets |
|---|---|---|---|---|---|---|
| Cmax (Maximum Measured Concentration of the Analyte in Plasma); Empagliflozin | 886 ± 27.3 | 810 ± 28.1 | 559 ± 29.0 | 601 ± 25.0 | 1010 ± 27.0 | 963 ± 29.7 |
Cmax (maximum measured concentration of the analyte in plasma); Metformin
| ng/mL | High Dose, Fasted: 1 FDC Tablet | High Dose, Fasted: 3 Single Tablets | High Dose, Fed: 1 FDC Tablet | High Dose, Fed: 3 Single Tablets | Low Dose, Fasted: 2 FDC Tablets | Low Dose, Fasted: 4 Single Tablets |
|---|---|---|---|---|---|---|
| Cmax (Maximum Measured Concentration of the Analyte in Plasma); Metformin | 822 ± 37.4 | 851 ± 28.8 | 1180 ± 27.4 | 1070 ± 22.8 | 1300 ± 34.4 | 1330 ± 41.3 |
AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Metformin
| ng*h/mL | High Dose, Fasted: 1 FDC Tablet | High Dose, Fasted: 3 Single Tablets | High Dose, Fed: 1 FDC Tablet | High Dose, Fed: 3 Single Tablets | Low Dose, Fasted: 2 FDC Tablets | Low Dose, Fasted: 4 Single Tablets |
|---|---|---|---|---|---|---|
| AUC 0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity); Metformin | 6490 ± 35.2 | 6790 ± 29.6 | 13200 ± 24.0 | 13200 ± 21.6 | 10500 ± 41.9 | 10400 ± 39.9 |
Collected over From first trial medication intake until next intake or the end-of-trial visit, 10 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| High Dose, Fasted: 1 FDC Tablet | — | 0/23 (0%) | 4/23 (17.4%) |
| High Dose, Fasted: 3 Single Tablets | — | 0/23 (0%) | 1/23 (4.3%) |
| High Dose, Fed: 1 FDC Tablet | — | 0/24 (0%) | 1/24 (4.2%) |
| High Dose, Fed: 3 Single Tablets | — | 0/24 (0%) | 2/24 (8.3%) |
| Low Dose, Fasted: 2 FDC Tablets | — | 0/24 (0%) | 4/24 (16.7%) |
| Low Dose, Fasted: 4 Single Tablets | — | 0/24 (0%) | 1/24 (4.2%) |
| Event | High Dose, Fasted: 1 FDC Tablet | High Dose, Fasted: 3 Single Tablets | High Dose, Fed: 1 FDC Tablet | High Dose, Fed: 3 Single Tablets | Low Dose, Fasted: 2 FDC Tablets | Low Dose, Fasted: 4 Single Tablets |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/23 | 0/23 | 0/24 | 1/24 | 2/24 | 0/24 |
| Abdominal painGastrointestinal disorders | 0/23 | 0/23 | 0/24 | 0/24 | 3/24 | 0/24 |
| NauseaGastrointestinal disorders | 2/23 | 1/23 | 1/24 | 2/24 | 0/24 | 1/24 |
Treated Set (TS): This patient set includes all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.
| Age, Continuous(years) | High Dose, Fasted | High Dose, Fed | Low Dose, Fasted | Total |
|---|---|---|---|---|
| Mean | 32.4 ± 8.7 | 34.2 ± 9.2 | 30.8 ± 8.4 | 32.5 ± 8.8 |
| Gender(Participants) | High Dose, Fasted | High Dose, Fed | Low Dose, Fasted | Total |
|---|---|---|---|---|
| Female | 10 | 10 | 10 | 30 |
| Male | 13 | 14 | 14 | 41 |
The record gives a start of Oct 2013, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Metformin